In NMOSD patients, the positive rate of AQP4 antibodies was determined to be 81.8%, and the clinical subtypes included optic neuritis (ON, 21.2%), myelitis (TM, 34.8%), and optic neuromyelitis (ON+TM, 43.9%). The gene discussed is AQP4; the disease is myelitis.